MIYUN, China - Marylandian -- Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) issued by the Netherlands Medicines Evaluation Board (MEB) in accordance with the relevant regulations of the European Medicines Agency.

Certificate information:

• Company name: Beijing Beilu pharmaceutical Co., Ltd.
• Manufacturing address: No.3 Shuiyuan West Road, Miyun District, Beijing, China
• Registration number: RVG 132878
• Drug name: Iohexol injection 350mg(I)/ml
• Issuing authority: Netherlands Medicines Evaluation Board (MEB)

The successful registration of Iohexol Injection in Netherland indicates that the product has undergone rigorous scientific evaluation by EMA, confirming its compliance with EU Good Manufacturing Practice (GMP), quality, safety and efficacy standards. This authorization enables commercial distribution in EU-approved countries. It creates conditions for speeding up the Mutual recognition procedures(MRP) among EU countries such as Germany, France, Italy and others as well. This will help Beilu Pharmaceutical further promote the expansion of its overseas market and enhance the international market competitiveness of its contrast agent products, which is expected to have a positive impact on the company's operations in the future.

More on Marylandian

• DuoKey to Unveil Encrypted Financial Intelligence Use Case at GISEC Global 2025
• Storytime AI Named Semifinalist in 2025 Milken-Penn GSE Education Business Plan Competition
• MedStar Health Announced as the Only Acute Care Health System in the Region to Earn Inaugural Recognition for Well-Being Excellence
• Mission 3A Establishes Healthcare Advisory Board with Addition of Industry Leaders Patrick Fisher, Kevin Cordell, and Dr. Greg Berlet
• SSATI Completes Acquisition of Invex Technology Solutions and ITIC Corporation's Government Support Services

Contact Information:
Beijing Beilu Pharmaceutical Co., Ltd.
https://www.beilupharma.com/
yanglm@beilupharma.com